A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
Latest Information Update: 11 Oct 2023
At a glance
- Drugs Cannabidiol (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors GW Research
Most Recent Events
- 13 Apr 2022 Status changed from recruiting to discontinued. This study was terminated based on a business decision by the Sponsor.
- 20 Aug 2021 Planned End Date changed from 1 Apr 2022 to 1 Dec 2022.
- 20 Aug 2021 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2022.